Back | Next |
home / stock / bivi / bivi message board
Subject | By | Source | When |
---|---|---|---|
and the shorts continue | 02opida | investorshub | 05/30/2023 7:00:52 AM |
$BIVI great article | noretreat | investorshub | 05/30/2023 1:04:06 AM |
Looks pretty positive | zerohedge | investorshub | 05/29/2023 5:10:19 AM |
great news | McMagyar | investorshub | 05/28/2023 6:54:09 PM |
Time for this to show some returns | hedge_fun | investorshub | 05/27/2023 3:38:04 PM |
This one will float along and then #slurp | zerohedge | investorshub | 03/31/2023 3:14:03 PM |
So many biopharma undervalued with great news already | McMagyar | investorshub | 03/22/2023 10:48:19 PM |
This is probably one of the best plays | zerohedge | investorshub | 03/22/2023 9:48:46 PM |
Why doesnt news on psirohsis success hit screen? https://www.msn.com/en-us/hea | McMagyar | investorshub | 03/16/2023 9:07:43 AM |
The ride to 100 starts now | akamaii | investorshub | 03/15/2023 8:56:30 PM |
znewcar1: $BIVI 22% v1,1M C6.96 f34,987M H7.44 ML4.78 | znewcar1 | investorshangout | 02/23/2023 9:50:23 PM |
Seeking Alpha has an opinion on BIV | conix | investorshub | 02/20/2023 5:41:50 PM |
$BIVI | Crapola2theleft | investorshub | 02/02/2023 6:00:26 PM |
https://seekingalpha.com/article/4570108-biovie-inc-stock-catalyst-rich-year-ahe | McMagyar | investorshub | 01/16/2023 3:13:54 PM |
Brutal pullback the last 2 days. Traders.. | hedge_fun | investorshub | 12/20/2022 8:58:52 PM |
znewcar1: $BIVI 29% v5,0M c12.29 f30,5M H13.75 ML4.11 off a dip for two days then turn around to HH | znewcar1 | investorshangout | 12/15/2022 12:52:07 AM |
due for a pullback, but who knows? | noretreat | investorshub | 12/14/2022 6:48:36 PM |
We have liftoff. Sum bi!ch what a | hedge_fun | investorshub | 12/14/2022 5:04:59 PM |
lol. | noretreat | investorshub | 12/14/2022 5:02:47 PM |
Everyone take a look. Certainly not selling now. | noretreat | investorshub | 12/14/2022 4:56:16 PM |
News, Short Squeeze, Breakout and More Instantly...
BioVie Inc. Company Name:
BIVI Stock Symbol:
OTCMKTS Market:
Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim, an anti-inflammatory and insulin-sensitizer that permeates the blood brain barrier, could represent a novel oral treatment targeting a...
“Bezisterim” has been approved as the non-proprietary name for NE3107 Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammation CARSON CITY, Nev., April 25, 2024 (GLOBE NEWSWIRE) -- BioV...
CARSON CITY, Nev., April 18, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, to...